- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- AVA6103
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–678
of 678
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Exemestane, Gamma-Secretase Inhibitor RO4929097, Goserelin Acetate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 1 more
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
- Interventions
- Palbociclib, Tamoxifen
- Drug
- Lead sponsor
- Oana Danciu, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more
- Conditions
- Cognition, Aging
- Interventions
- tamoxifen, raloxifene
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 1,498 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2008
- U.S. locations
- 127
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Letrozole
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Lowell, Massachusetts